Rein Therapeutics Inc (RNTX) — Cash Flow-to-Debt Ratio
Latest as of March 2026:
-0.23x
Rein Therapeutics Inc (RNTX) has a Cash Flow-to-Debt Ratio of -0.23x as of March 2026, meaning its operating cash flow of $-3.42 Million could theoretically repay 0% of its total liabilities ($14.70 Million) in one year. See Rein Therapeutics Inc (RNTX) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.23x
Operating CF / Total Liabilities
Operating Cash Flow
$-3.42 Million
USD
Total Liabilities
$14.70 Million
USD
Data as of
Mar 2026
Most recent filing
Rein Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Rein Therapeutics Inc across 11 annual periods. For the full cash flow conversion analysis, see Rein Therapeutics Inc operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for Rein Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for Rein Therapeutics Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.67x | $-19.36 Million | $7.24 Million | ▼ -78.1% |
| 2024 | -1.50x | $-22.29 Million | $14.85 Million | ▼ -651.3% |
| 2023 | -0.20x | $-19.81 Million | $99.12 Million | ▲ +97.3% |
| 2022 | -7.35x | $-24.86 Million | $3.38 Million | ▼ -41.6% |
| 2021 | -5.19x | $-23.75 Million | $4.58 Million | ▼ -5.9% |
| 2020 | -4.90x | $-20.48 Million | $4.18 Million | ▼ -92.9% |
| 2019 | -2.54x | $-26.47 Million | $10.43 Million | ▲ +2.6% |
| 2018 | -2.61x | $-27.93 Million | $10.71 Million | ▲ +37.9% |
| 2017 | -4.20x | $-20.53 Million | $4.89 Million | ▼ -3641.6% |
| 2016 | -0.11x | $-15.01 Million | $133.83 Million | ▲ +3.9% |
| 2015 | -0.12x | $-11.71 Million | $100.26 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.